Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-09-06
- Target Recruit Count
- 165
- Registration Number
- NCT00006154
- Locations
- 🇨🇦
Centre Hospitalier de la Universite de Montreal (CHUM), Montreal, Quebec, Canada
🇨🇦Centre de traitment d'immunodeficience, Montreal, Quebec, Canada
🇨🇦Viridae Clinical Sciences / University of British Columbia, Vancouver, British Columbia, Canada
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 100
- Registration Number
- NCT00002423
- Locations
- 🇺🇸
IDC Research Initiative, Altamonte Springs, Florida, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Kansas City AIDS Research Consortium, Kansas City, Missouri, United States
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 475
- Registration Number
- NCT00000912
- Locations
- 🇺🇸
USC Univ Hosp & Ambulatory Hlth Care Ctr / USC Med Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 1710
- Registration Number
- NCT00000922
- Locations
- 🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
🇺🇸Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States
An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002205
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
- Conditions
- HIV Infections
- Locations
- 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 55
- Registration Number
- NCT00004855
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Denver Dept of Health and Hosps, Denver, Colorado, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00011479
- Locations
- 🇺🇸
Med College of Georgia, Augusta, Georgia, United States
🇺🇸Children's Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Los Angeles County - USC Med Ctr, Los Angeles, California, United States
A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 42
- Registration Number
- NCT00006152
- Locations
- 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸Univ of Texas Galveston, Galveston, Texas, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 32
- Registration Number
- NCT00000865
- Locations
- 🇺🇸
UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.